 "BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs")
Shares of pharmaceutical companies were on a roll at the bourses on Friday, with the S&P BSE Healthcare index surging nearly 3 per cent to hit its record high on the back of positive news flow.
Laurus Labs, Dr Reddy’s Laboratories and Apollo Hospitals from the index hit their respective record highs, while Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma and Hikal scaled their respective 52-week highs on the BSE.
At 09:48 am, the S&P BSE Healthcare index, the top gainer among sectoral indices, was up 2.9 per cent at 20,282 points, as compared to 0.4 per cent rise in the S&P BSE Sensex. The healthcare index hit a record high of 20,294 in intra-day trade today.
In a positive development for Lupin and Cipla, Perrigo has announced a voluntary recall of its albuterol sulphate inhalation aerosols in the US over concerns that some units may not dispense properly due to clogging issues. Shares of Lupin rallied 7 per cent to Rs 1,107, while Cipla surged 5 per cent to Rs 790 on the BSE.
Dr Reddy's hit a fresh record high of Rs 5,090, up 6 per cent, after the company entered into a settlement agreement with Celgene Corp. In the past three days, the stock has gained 15 per cent after the firm said it has been roped-in by Russia-based Russian Direct Investment Fund (RDIF) to distribute 100 million Covid-19 vaccine doses in India.
Laurus Labs, too, hit a fresh record high of Rs 1,480 after rising 5 per cent tday. The stock has rallied 18 per cent thus far in the current week on expectation of strong earnings in July-September quarter (Q2FY21). The pharmaceutical company's stock was trading higher for the tenth straight day.
Meanwhile, the stock of Laurus Labs will turn ex-date for 1:5 stock split on September 29, 2020. The company's board of directors has fixed September 30, 2020, as the record date for the sub-division of equity shares of the company from the existing face value of Rs 10 each to Rs 2 each. The company announced, on April 30, its stock split plan to make the stock more affordable for the small retail investors and increase liquidity.
Laurus Labs, Dr Reddy’s Laboratories and Apollo Hospitals from the index hit their respective record highs, while Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma and Hikal scaled their respective 52-week highs on the BSE.
At 09:48 am, the S&P BSE Healthcare index, the top gainer among sectoral indices, was up 2.9 per cent at 20,282 points, as compared to 0.4 per cent rise in the S&P BSE Sensex. The healthcare index hit a record high of 20,294 in intra-day trade today.
In a positive development for Lupin and Cipla, Perrigo has announced a voluntary recall of its albuterol sulphate inhalation aerosols in the US over concerns that some units may not dispense properly due to clogging issues. Shares of Lupin rallied 7 per cent to Rs 1,107, while Cipla surged 5 per cent to Rs 790 on the BSE.
Dr Reddy's hit a fresh record high of Rs 5,090, up 6 per cent, after the company entered into a settlement agreement with Celgene Corp. In the past three days, the stock has gained 15 per cent after the firm said it has been roped-in by Russia-based Russian Direct Investment Fund (RDIF) to distribute 100 million Covid-19 vaccine doses in India.
Laurus Labs, too, hit a fresh record high of Rs 1,480 after rising 5 per cent tday. The stock has rallied 18 per cent thus far in the current week on expectation of strong earnings in July-September quarter (Q2FY21). The pharmaceutical company's stock was trading higher for the tenth straight day.
Meanwhile, the stock of Laurus Labs will turn ex-date for 1:5 stock split on September 29, 2020. The company's board of directors has fixed September 30, 2020, as the record date for the sub-division of equity shares of the company from the existing face value of Rs 10 each to Rs 2 each. The company announced, on April 30, its stock split plan to make the stock more affordable for the small retail investors and increase liquidity.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| NATCO PHARMA | 863.05 | 776.45 | 11.2 |
| NEULAND LABS. | 1192.00 | 1123.95 | 6.1 |
| LUPIN | 1094.20 | 1037.95 | 5.4 |
| DISHMAN CARBOGEN | 179.15 | 170.65 | 5.0 |
| LAURUS LABS | 1473.45 | 1405.50 | 4.8 |
| DR REDDY'S LABS | 5048.70 | 4826.60 | 4.6 |
| J B CHEM & PHARM | 1113.60 | 1068.40 | 4.2 |
| GLENMARK PHARMA. | 513.10 | 492.35 | 4.2 |
| CIPLA | 783.25 | 752.05 | 4.2 |
| FERMENTA BIOTEC. | 379.20 | 366.25 | 3.5 |
| HIKAL | 189.50 | 183.05 | 3.5 |
| DIVI'S LAB. | 3320.00 | 3211.15 | 3.4 |
| WOCKHARDT | 305.55 | 296.05 | 3.2 |
| SUN PHARMA.INDS. | 527.80 | 511.85 | 3.1 |
| CAPLIN POINT LAB | 589.75 | 572.15 | 3.1 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%